{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T04:26:06Z","timestamp":1791951966469,"version":"4.3.4"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T00:00:00Z","timestamp":1773360000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Shenzhen Key Medical Discipline Construction Fund","award":["SZXK009"],"award-info":[{"award-number":["SZXK009"]}]},{"DOI":"10.13039\/501100012151","name":"Sanming Project of Medicine in Shenzhen","doi-asserted-by":"publisher","award":["SZSM202211013"],"award-info":[{"award-number":["SZSM202211013"]}],"id":[{"id":"10.13039\/501100012151","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shenzhen High-level Hospital Construction Fund"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,30]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and hypothesis<\/jats:title>\n                    <jats:p>Primary membranous nephropathy (pMN) is a common cause of nephrotic syndrome in adults. Rituximab (RTX) is a first-line therapy targeting B cells; however, 30%\u201340% of MN patients exhibit treatment resistance or relapse. Studies have shown that anti-rituximab antibodies (ARA) may lead to RTX resistance through mechanisms such as drug neutralization. The objective of this study is to explore the relationship between the emergence of ARA and the clinical efficacy of initial RTX treatment in adult MN.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Patients with MN who received RTX therapy were included in this study. Clinical data and laboratory results of the patients were collected, and ARA levels in serum samples were measured using a commercial ELISA kit. The impact of ARA on the clinical outcomes of MN patients treated with RTX was analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among 58 patients with membranous nephropathy who received initial RTX treatment, 11 patients (19.0%) tested positive for ARA. ARA were identified after a median of 9.3 months (IQR 8.2\u201311.1) following the last RTX injection. Among the patients who received initial RTX treatment and were monitored for over 6 months, ARA-positive patients (n\u00a0=\u00a011) exhibited a higher relapse rate (80.0% vs. 24.1%, P\u00a0=\u00a0.029) than ARA-negative patients (n\u00a0=\u00a041), which was also confirmed by Kaplan\u2013Meier analysis (log-rank test, P\u00a0=\u00a0.027). At 6 months post-initial RTX, ARA-positive patients demonstrated higher B-cell levels (p=\u00a0.021). Four RTX-resistant and ARA-positive patients achieved clinical remission with obinutuzumab, with a median remission time of 4.8 months (IQR 3.0\u20136.8).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirms that adult patients with MN who are ARA positive have a higher relapse rate after initial RTX treatment. Patients who are RTX-resistant and ARA positive can achieve rapid clinical remission after receiving obinutuzumab treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ndt\/gfag054","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:48:28Z","timestamp":1773330508000},"page":"1849-1857","source":"Crossref","is-referenced-by-count":3,"title":["Association between anti-rituximab antibodies and treatment efficacy of rituximab in membranous nephropathy"],"prefix":"10.1093","volume":"41","author":[{"given":"Di","family":"Wu","sequence":"first","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zigan","family":"Xu","sequence":"additional","affiliation":[{"name":"The First Affiliated Hospital of Jinan University Department of Nephrology, , Guangzhou ,","place":["China"]},{"name":"Shenzhen Longhua District Central Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricong","family":"Xu","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-0273-1364","authenticated-orcid":false,"given":"Wen","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4226-8135","authenticated-orcid":false,"given":"Zhihang","family":"Su","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiting","family":"Li","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuna","family":"Chen","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haofei","family":"Hu","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liling","family":"Wu","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xue","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biao","family":"Huang","sequence":"additional","affiliation":[{"name":"College of Life Sciences and Medicine, Zhejiang Sci-Tech University , Hangzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingbo","family":"liu","sequence":"additional","affiliation":[{"name":"Jiuming Medical Technology Co., Ltd , Changzhou ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaodong","family":"Luan","sequence":"additional","affiliation":[{"name":"Shenzhen Longhua District Central Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Wan","sequence":"additional","affiliation":[{"name":"Shenzhen Second People\u2019s Hospital Department of Nephrology, , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,13]]},"reference":[{"key":"2026093006065251000_bib1","doi-asserted-by":"publisher","first-page":"983","DOI":"10.2215\/CJN.11761116","article-title":"Primary membranous nephropathy","volume":"12","author":"Couser","year":"2017","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026093006065251000_bib2","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3390\/biom11040513","article-title":"Mechanisms of primary membranous nephropathy","volume":"11","author":"Gu","year":"2021","journal-title":"Biomolecules"},{"key":"2026093006065251000_bib3","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1681\/ASN.2009080861","article-title":"Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy","volume":"21","author":"Polanco","year":"2010","journal-title":"J Am Soc Nephrol"},{"key":"2026093006065251000_bib4","doi-asserted-by":"publisher","first-page":"1600","DOI":"10.1038\/ki.1995.453","article-title":"A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathy","volume":"48","author":"Ponticelli","year":"1995","journal-title":"Kidney Int"},{"key":"2026093006065251000_bib5","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa0810457","article-title":"M-type phospholipase A2Receptor as target antigen in idiopathic membranous nephropathy","volume":"361","author":"Beck","year":"2009","journal-title":"N Engl J Med"},{"key":"2026093006065251000_bib6","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1681\/ASN.2010111125","article-title":"Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy","volume":"22","author":"Beck","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2026093006065251000_bib7","doi-asserted-by":"publisher","first-page":"7359","DOI":"10.1038\/sj.onc.1206939","article-title":"Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance","volume":"22","author":"Smith","year":"2003","journal-title":"Oncogene"},{"key":"2026093006065251000_bib8","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1016\/S0140-6736(02)11042-7","article-title":"Rituximab for idiopathic membranous nephropathy","volume":"360","author":"Remuzzi","year":"2002","journal-title":"Lancet"},{"key":"2026093006065251000_bib9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.5114\/aoms.2020.99899","article-title":"Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis","volume":"19","author":"Zhong","year":"2023","journal-title":"Arch Med Sci"},{"key":"2026093006065251000_bib10","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1007\/s11255-020-02633-5","article-title":"Rituximab for the management of idiopathic membranous nephropathy: a meta-analysis","volume":"53","author":"Huang","year":"2020","journal-title":"Int Urol Nephrol"},{"key":"2026093006065251000_bib11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1681\/ASN.2016040449","article-title":"Rituximab for severe membranous nephropathy: a 6-month trial with extended follow-up","volume":"28","author":"Dahan","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2026093006065251000_bib12","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa1814427","article-title":"Rituximab or cyclosporine in the treatment of membranous nephropathy","volume":"381","author":"Fervenza","year":"2019","journal-title":"N Engl J Med"},{"key":"2026093006065251000_bib13","doi-asserted-by":"publisher","first-page":"2188","DOI":"10.2215\/CJN.05080610","article-title":"Rituximab therapy in idiopathic membranous nephropathy: a 2-year study","volume":"5","author":"Fervenza","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026093006065251000_bib14","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1097\/01.ASN.0000071511.35221.B3","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"14","author":"Ruggenenti","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2026093006065251000_bib15","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1681\/ASN.2012020181","article-title":"Rituximab in idiopathic membranous nephropathy","volume":"23","author":"Ruggenenti","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"2026093006065251000_bib16","doi-asserted-by":"publisher","first-page":"972","DOI":"10.1681\/ASN.2020071091","article-title":"Rituximab or cyclophosphamide in the treatment of membranous nephropathy: the RI-CYCLO randomized trial","volume":"32","author":"Scolari","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2026093006065251000_bib17","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.kint.2020.10.014","article-title":"The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy","volume":"99","author":"Fern\u00e1ndez-Ju\u00e1rez","year":"2021","journal-title":"Kidney Int"},{"key":"2026093006065251000_bib18","doi-asserted-by":"publisher","first-page":"859419","DOI":"10.3389\/fimmu.2022.859419","article-title":"Advances in the management of primary membranous nephropathy and rituximab-refractory membranous nephropathy","volume":"13","author":"Teisseyre","year":"2022","journal-title":"Front Immunol"},{"key":"2026093006065251000_bib19","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4103\/ijmr.IJMR_312_19","article-title":"Development of anti-rituximab antibodies in rituximab-treated patients: related parameters & consequences","volume":"155","author":"Jafarzadeh","year":"2022","journal-title":"Indian J Med Res"},{"key":"2026093006065251000_bib20","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1093\/rheumatology\/keac608","article-title":"Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupus","volume":"62","author":"Wincup","year":"2023","journal-title":"Rheumatology"},{"key":"2026093006065251000_bib21","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1136\/annrheumdis-2019-215200","article-title":"Presence of anti-rituximab antibodies predicts infusion-related reactions in patients with systemic lupus erythematosus","volume":"78","author":"Wincup","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2026093006065251000_bib22","doi-asserted-by":"publisher","first-page":"3069","DOI":"10.3389\/fimmu.2019.03069","article-title":"Neutralizing anti-rituximab antibodies and relapse in membranous nephropathy treated with rituximab","volume":"10","author":"Boyer-Suavet","year":"2020","journal-title":"Front Immunol"},{"key":"2026093006065251000_bib23","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/sj.ki.5002628","article-title":"Rituximab treatment of idiopathic membranous nephropathy","volume":"73","author":"Fervenza","year":"2008","journal-title":"Kidney Int"},{"key":"2026093006065251000_bib24","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1016\/j.ekir.2025.04.059","article-title":"Anti-rituximab antibodies occurrence and clinical outcomes in patients with primary membranous nephropathy","volume":"10","author":"Allinovi","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026093006065251000_bib25","doi-asserted-by":"publisher","first-page":"785","DOI":"10.2215\/CJN.0000000000000152","article-title":"Risk factors associated with the occurrence of anti-rituximab antibodies in membranous nephropathy","volume":"18","author":"Teisseyre","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"key":"2026093006065251000_bib26","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1016\/j.ekir.2021.01.022","article-title":"Analysis and management of rituximab resistance in PLA2R1-associated membranous nephropathy","volume":"6","author":"Teisseyre","year":"2021","journal-title":"Kidney Int Rep"},{"key":"2026093006065251000_bib27","doi-asserted-by":"publisher","first-page":"738788","DOI":"10.3389\/fimmu.2021.738788","article-title":"Rituximab immunomonitoring predicts remission in membranous nephropathy","volume":"12","author":"Teisseyre","year":"2021","journal-title":"Front Immunol"},{"key":"2026093006065251000_bib28","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1093\/ndt\/gfae230","article-title":"Obinutuzumab versus rituximab for the treatment of refractory primary membranous nephropathy","volume":"40","author":"Xu","year":"2025","journal-title":"Nephrol Dial Transplant"},{"key":"2026093006065251000_bib29","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.ekir.2024.12.012","article-title":"Obinutuzumab and ofatumumab are more effective than rituximab in the treatment of membranous nephropathy patients with anti-rituximab antibodies","volume":"10","author":"Teisseyre","year":"2025","journal-title":"Kidney Int Rep"},{"key":"2026093006065251000_bib30","doi-asserted-by":"publisher","first-page":"2509","DOI":"10.1016\/j.ekir.2022.08.006","article-title":"Circulating anti-rituximab antibodies do not affect response to rituximab in steroid-dependent nephrotic syndrome","volume":"7","author":"Angeletti","year":"2022","journal-title":"Kidney Int Rep"},{"key":"2026093006065251000_bib31","doi-asserted-by":"publisher","first-page":"1024068","DOI":"10.3389\/fimmu.2022.1024068","article-title":"Implications of rituximab pharmacokinetic and pharmacodynamic alterations in various immune-mediated glomerulopathies and potential anti-CD20 therapy alternatives","volume":"13","author":"Hartinger","year":"2022","journal-title":"Front Immunol"},{"key":"2026093006065251000_bib32","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long-term efficacy of infliximab in Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N Engl J Med"},{"key":"2026093006065251000_bib33","doi-asserted-by":"publisher","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"2026093006065251000_bib34","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/j.1365-2141.2010.08428.x","article-title":"Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells","volume":"152","author":"Patz","year":"2010","journal-title":"Br J Haematol"},{"key":"2026093006065251000_bib35","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1016\/j.ekir.2020.06.030","article-title":"Obinutuzumab is effective for the treatment of refractory membranous nephropathy","volume":"5","author":"Sethi","year":"2020","journal-title":"Kidney Int Rep"},{"key":"2026093006065251000_bib36","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1053\/j.ajkd.2020.02.444","article-title":"Successful treatment of patients with refractory PLA2R-associated membranous nephropathy with obinutuzumab: a report of 3 cases","volume":"76","author":"Klomjit","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2026093006065251000_bib37","doi-asserted-by":"publisher","first-page":"1594","DOI":"10.2215\/CJN.0000000000000555","article-title":"Comparison of obinutuzumab and rituximab for treating primary membranous nephropathy","volume":"19","author":"Hu","year":"2024","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfag054\/67338722\/gfag054.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/10\/1849\/67338722\/gfag054.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/41\/10\/1849\/67338722\/gfag054.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T10:06:59Z","timestamp":1790762819000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/41\/10\/1849\/8519153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,13]]},"references-count":37,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,3,13]]},"published-print":{"date-parts":[[2026,9,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfag054","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,3,13]]}}}